Cancer

Endometriosis is not typically life-threatening, but it can become medically serious—especially when it involves organs like the bowel, bladder, ureters (the tubes that drain the kidneys), or even areas higher in the abdomen. In advanced cases, deep disease and scarring can distort anatomy and, rarely, lead to complications such as bowel obstruction or silent kidney damage from ureteral blockage. Endometriosis can also occur outside the pelvis, including in the chest; for a small subset of patients, thoracic involvement can be associated with events like a recurrent collapsed lung around the menstrual cycle.

Another reason this question comes up is cancer fear. Endometriosis itself is not cancer, and malignant transformation is uncommon, but certain lesions—especially ovarian endometriomas and deep disease—are associated with a higher risk of specific ovarian cancer subtypes in a small minority of patients. The key is not to panic, but to take persistent symptoms, growing masses, organ-related symptoms (urinary or bowel changes), or new patterns seriously. If you’re concerned about severity or “could this be dangerous,” our team can help evaluate where disease may be present and whether strategic excision surgery is appropriate to protect organs and improve long-term health.

Yes—endometriosis can rarely undergo malignant transformation, but for the vast majority of people it does not “turn into cancer.” Endometriosis itself is not cancer, even though it can behave in cancer-like ways (invading tissues, scarring, and spreading beyond the pelvis). The best-supported association in research is with certain ovarian cancer subtypes, especially clear cell and endometrioid ovarian cancers, and the risk appears highest when the ovaries are involved (such as with endometriomas).

What matters most is context: your age, family history/genetics, imaging findings, and whether a cyst or mass is changing over time. If you’re worried about an endometrioma, deep disease, or persistent symptoms that don’t fit your usual pattern, our team can evaluate your full picture and help you understand what’s reassuring versus what deserves closer workup. If surgery is appropriate, strategic minimally invasive excision can both treat disease and allow tissue diagnosis when needed—so you’re not left guessing. Reach out to schedule a consultation if you’d like a personalized risk discussion and a clear plan.

Adenomyosis itself is not cancer. It’s a benign condition where endometrial-like tissue grows into the muscular wall of the uterus, and it can cause heavy bleeding, painful periods, and an enlarged, tender uterus—but it doesn’t “turn into” cancer in the way many patients fear.

That said, adenomyosis can sometimes be seen alongside uterine (endometrial) cancer on hysterectomy pathology, which understandably raises questions about whether the two are connected. Current evidence doesn’t show that adenomyosis protects you from cancer or that it clearly causes cancer, and research on risk relationships is still evolving and can be mixed depending on the cancer type studied.

If you’re worried because of symptoms like heavier bleeding than usual, bleeding between periods, or new/worsening pelvic pain—especially if your symptoms are changing—our team can help you sort out what’s most likely going on, what testing is appropriate, and what treatment options (including surgical options when needed) make sense for your goals.

In most cases, endometriosis does not kill you. It is not cancer, but it can behave in aggressive ways—invading tissues, scarring organs, and (more rarely) spreading beyond the pelvis—which is why it can feel frightening and why symptoms can be so disruptive.

That said, endometriosis can become dangerous when it affects critical structures like the bowel, bladder, or ureters (the tubes that drain urine from the kidneys), or when an ovarian endometrioma or deep disease raises concern for abnormal growth. There is also a small, uncommon possibility of malignant transformation in some endometriosis lesions, which is one reason we take persistent masses, worsening symptoms, or post-menopausal symptoms seriously.

If this question is coming from a place of fear—like a growing ovarian cyst, unexplained weight loss, persistent bloating, or symptoms that are steadily worsening—our team can help you sort out what’s most likely, what needs closer evaluation, and what your options are, including definitive diagnosis and treatment with minimally invasive excision when appropriate.

Leaving an endometrioma in place can carry risks such as gradual growth with increasing pelvic pain and inflammation, and in rare cases acute complications like rupture or ovarian torsion. There is also a small increased lifetime risk of certain ovarian cancers compared with the general population, but the absolute risk remains low—especially when imaging shows features typical of an endometrioma.

Monitoring is usually done with repeat imaging, most often pelvic ultrasound at intervals (commonly every 6–12 months), along with symptom check-ins. We pay close attention to changes like rapid growth, new solid components, or internal blood flow, as these can prompt a different workup or a discussion about treatment. If symptoms escalate or the cyst begins to interfere with ovarian function or fertility planning, our team can review your options and help you decide whether continued observation or surgery makes the most sense for you.

Benign uterine fibroids almost never “turn into” cancer. A true uterine leiomyosarcoma is rare and typically arises independently rather than from a pre-existing fibroid, which is why the overall risk remains low.

The red flags we take most seriously include a new or rapidly enlarging uterine mass after menopause, unusual or concerning findings on ultrasound or MRI, and bleeding patterns that don’t fit your prior history (especially new bleeding after menopause). When there are concerning features, our team focuses on a careful history review and expert imaging interpretation—often with MRI—to better assess risk and guide next steps. The only definitive way to diagnose leiomyosarcoma is through pathology after tissue is removed, so if you’re worried about your symptoms or imaging report, you can reach out to schedule a consultation with us for a personalized assessment.

Endometriosis is associated with a slightly higher lifetime risk of certain ovarian cancers, but the overall (absolute) risk for most people remains low. When it comes to menopause hormone therapy, the research in people with prior endometriosis is limited, so decisions are usually individualized based on your symptoms, history, and whether you still have a uterus.

In general, if hormone therapy is used and the uterus is present, combined therapy (estrogen with a progestogen) is often preferred over estrogen-only approaches to help balance benefits and risk. We also take any new or changing symptoms seriously—especially postmenopausal bleeding, persistent bloating, or progressively worsening pelvic pain—and use them as cues to evaluate promptly rather than “wait and see.” If you have a strong family history of cancer or a known genetic mutation, we recommend scheduling a consultation with our team so we can tailor a plan that prioritizes both symptom relief and long-term safety.

There is not a universal cancer-screening program recommended solely for endometriosis or adenomyosis, but that does not mean cancer risk should be ignored. Endometriosis is not cancer, and most people with it will never develop cancer, yet research does suggest an increased risk of certain ovarian cancers, which is why individual risk assessment matters.

Tests such as CA-125 or CA19-9 are not reliable routine screening tools by themselves, because they can be elevated for many non-cancer reasons, including endometriosis itself. Instead, the right next step depends on your personal risk profile—especially if you have a strong family history of ovarian, breast, uterine, or colon cancer, a known or suspected genetic predisposition, an endometrioma, deep infiltrating disease, or new concerning symptoms.

In those situations, closer evaluation, imaging, follow-up, and sometimes genetic counseling or testing may be appropriate. Our team can help you understand your individual risk and decide whether additional evaluation makes sense.